Assistant Professor and Associate Consultant, Microbiome Program,
Dr. Yuguang Liu is an Assistant Professor and Associate Consultant in the Microbiome Program, Center for Individualized Medicine at Mayo Clinic. She is also affiliated with the Department of Physiology and Biomedical Engineering and the Department of Immunology. Trained as an electrical engineer, Yuguang Liu’s research interests focus on developing microfluidic technologies for various applications, from basic and translational research in medicine to the exploration of the limits of life on extraterrestrial bodies. She has expertise in developing microfluidic devices for studying the genomic adaption of single microbial cells under unusual environments, interaction between immune and microbial cells, rapid bacterial diagnosis and monitoring immune responsiveness to cancer immunotherapies. Yuguang Liu is also a recent awardee of Maximizing Investigators' Research Award (MIRA) R35 from the National Institute of General Medical Sciences.
Microfluidics For High-Resolution Analysis of Genomic Adaptation, Rapid Immunodiagnostics and Beyond
Thursday, 30 November 2023 at 15:00
Add to Calendar ▼2023-11-30 15:00:002023-11-30 16:00:00Europe/LondonMicrofluidics For High-Resolution Analysis of Genomic Adaptation, Rapid Immunodiagnostics and BeyondLab-on-a-Chip and Microfluidics World Congress 2023 in Laguna Hills, CaliforniaLaguna Hills, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Microfluidic technologies are revolutionizing our scientific research and healthcare practices in many aspects. This talk is focused on how we develop and use microfluidic tools to investigate long-standing unanswered questions in fundamental processes in biology and disease mechanisms, as well as to contribute to unmet clinical needs. Briefly, we present 1) how microfluidic tools have advanced our understanding in single microbial cells’ ability to genomically adapt to extreme stresses in unusual environments (e.g.,high UV radiation, extreme temperature cycles) by analyzing their point mutation; 2) how we use microdroplets to solicit and study the interaction between microbes and immune cells on a single cell level, and 3) the integration of microsensors (impedance and modified electrochemical microsensors) with a digital microfluidic device to detect key indicators of immune responsiveness to immune checkpoint inhibitors (e.g., immune cell subpopulations, extracellular vesicles and soluble molecules), which can eventually provide a tool to closely monitor the therapeutic responsiveness to cancer immunotherapies in an automated manner.